Institut National de la Santé et de la Recherche Médicale (Inserm) UMR1096, Faculty of Medicine and Pharmacy, Rouen, France.
Program of Cardiovascular Diseases, CIMA Universidad de Navarra and IdiSNA, Pamplona, Spain; CIBERCV, Carlos III Institute of Health, Madrid, Spain.
J Am Coll Cardiol. 2020 Aug 11;76(6):735-744. doi: 10.1016/j.jacc.2020.05.076.
The cardiac lymphatic network plays a key role in regulation of myocardial extracellular volume and immune cell homeostasis. In different pathological conditions cardiac lymphatics undergo significant remodeling, with insufficient lymphatic function and/or lymphangiogenesis leading to fluid accumulation and development of edema. Additionally, by modulating the reuptake of tissue-infiltrating immune cells, lymphatics regulate immune responses. Available evidence suggests that both edema and inadequate immune response resolution may contribute to extracellular matrix remodeling and interstitial myocardial fibrosis. Interestingly, stimulation of lymphangiogenesis has been shown to improve cardiac function and reduce the progression of myocardial fibrosis during heart failure development after myocardial infarction. This review goes through the available clinical and experimental data supporting a role for cardiac lymphatics in cardiac disease, focusing on the current evidence linking poor cardiac lymphatic transport to the fibrogenic process and discussing potential avenues for novel biomarkers and therapeutic targets to limit cardiac fibrosis and dysfunction.
心脏淋巴管网络在调节心肌细胞外体积和免疫细胞稳态方面发挥着关键作用。在不同的病理条件下,心脏淋巴管经历了显著的重塑,其淋巴管功能不足和/或淋巴管生成导致液体积累和水肿的发展。此外,通过调节组织浸润免疫细胞的再摄取,淋巴管调节免疫反应。现有证据表明,水肿和免疫反应不足的解决可能有助于细胞外基质重塑和间质心肌纤维化。有趣的是,刺激淋巴管生成已被证明可改善心力衰竭发展期间心肌梗死后的心功能并减少心肌纤维化的进展。本综述回顾了支持心脏淋巴管在心脏疾病中的作用的现有临床和实验数据,重点介绍了将心脏淋巴管运输不良与纤维生成过程联系起来的现有证据,并讨论了限制心脏纤维化和功能障碍的新型生物标志物和治疗靶点的潜在途径。